STAT3 and ovarian carcinoma: In the current study, we investigated whether PARPi treatments in ovarian cancer patients induce STAT3 activation in tumor cells and the tumor immuno-microenvironment and whether PARPi-mediated STAT3 activation underlies PARPi resistance and immunosuppression in ovarian cancer.